Navigation Links
Par Pharmaceutical Receives Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg

WOODCLIFF LAKE, N.J., Aug. 20, 2013 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (sANDA) for bupropion hydrochloride (HCl) extended-release (ER) tablets USP (XL), 300 mg.  Bupropion HCl ER tablets USP (XL) is the generic version of WELLBUTRIN XL® and is indicated for the treatment of major depressive disorder (MDD).  Par's supply to the market of bupropion HCl ER tablets USP (XL), 150 mg and 300 mg, has been uninterrupted since originally approved in December 2006. 

In September 2012, FDA requested all generic drug companies marketing a version of bupropion HCl ER tablets, 300 mg, to conduct a fasting bioequivalence (BE) study comparing their bupropion HCl ER tablets, 300 mg, to GSK's WELLBUTRIN XL® (bupropion hydrochloride extended release) Tablets, 300 mg.  In December 2012, Par submitted a sANDA containing the requested study to FDA, which demonstrated in vivo bioequivalence of Par's bupropion HCl ER tablets USP (XL), 300 mg, to WELLBUTRIN XL® Tablets, 300 mg.  In April 2013, Par's sANDA was approved. 

Important Information About Bupropion HCl ER Tablets (XL) 
Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with a seizure disorder, in patients treated with ZYBAN® (bupropion hydrochloride extended-release tablets (XL)); WELLBUTRIN® (bupropion hydrochloride tablets), the immediate-release formulation; WELLBUTRIN SR® (bupropion hydrochloride extended-release tablets (SR)), the sustained-release formulation; or any other medications that contain bupropion because the incidence of seizure is dose dependent, in patients with a current or prior diagnosis of bulimia or anorexia nervosa because of a higher incidence of seizures noted in patients treated for bulimia with the immediate-release formulation of bupropion, and in patients undergoing abrupt discontinuation of alcohol or sedatives (including benzodiazepines). 

The concurrent administration of bupropion hydrochloride extended-release tablets (XL) and a monoamine oxidase (MAO) inhibitor is contraindicated.  At least 14 days should elapse between discontinuation of an MAO inhibitor and initiation of treatment with bupropion hydrochloride extended-release tablets (XL). 

Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients who have shown an allergic response to bupropion or the other ingredients that make up bupropion hydrochloride extended-release tablets (XL). 

A black box warning is associated with this product regarding Suicidality and Antidepressant Drugs.  Refer to full prescribing information for complete boxed warning. 

About Par Pharmaceutical Companies, Inc. 
Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals.  For press release and other company information, visit

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ferring Pharmaceuticals Provides Baby Quest Foundation Grant Recipients with Free Access to Fertility Medication
2. Johnson & Johnson Completes Acquisition Of Aragon Pharmaceuticals, Inc.
3. HedgePath Pharmaceuticals, Inc. Completes Reorganization Plan with Commonwealth Biotechnologies
4. National Pharmaceutical Council Studies New Formulary Decision-Making Tool
5. TetraLogic Pharmaceuticals Announces New Executives
6. Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises
7. Velocity Pharmaceutical Development and Remeditex Ventures Announce Collaboration Agreement and Initial Co-Investment
8. Pharmaceutical Companies Can Avoid Costly Launch Expenses by Leveraging and Pooling Sales and Promotional Resources
9. Cadence Pharmaceuticals Comments on USPTOs Non-Final, Initial Office Action on Reexamination of Patent
10. Japan Pharmaceutical Market Outlook
11. Cadence Pharmaceuticals Appoints Laureen DeBuono to its Board of Directors
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect Plugin ... whole new perspective by using the title layers in ProSlice Levels to split-up ... Levels contains over 30 Different presets to choose from. FCPX users can ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from ...
Breaking Medicine News(10 mins):